9/8/2024, 9:16:03 am

Lupin shares are up 90% in the last one year, JPMorgan sees more upside.

Brokerage firm JPMorgan has upgraded shares of drugmaker Lupin to "overweight" from its earlier rating of "neutral" saying the company's growth story has "more legs to grow" despite its significant outperformance recently. Shares of Lupin have rallied 90% in the last 12 months and 60% so far in 2024. JPMorgan has also raised its price target on Lupin to ₹2,400 from ₹1,440 earlier.